ID: ALA303714

Max Phase: Preclinical

Molecular Formula: C8H9N3

Molecular Weight: 147.18

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  NCc1nc2ccccc2[nH]1

Standard InChI:  InChI=1S/C8H9N3/c9-5-8-10-6-3-1-2-4-7(6)11-8/h1-4H,5,9H2,(H,10,11)

Standard InChI Key:  UCOSRTUSVXHIMK-UHFFFAOYSA-N

Associated Targets(Human)

Matrix metalloproteinase 9 6779 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lysyl oxidase homolog 2 834 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glutaminyl-peptide cyclotransferase 1121 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cytochrome P450 2B1 145 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 9 44 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2b (5-HT2b) receptor 321 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2c (5-HT2c) receptor 1134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2a (5-HT2a) receptor 3540 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 147.18Molecular Weight (Monoisotopic): 147.0796AlogP: 1.02#Rotatable Bonds: 1
Polar Surface Area: 54.70Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.49CX Basic pKa: 7.90CX LogP: 0.46CX LogD: -0.16
Aromatic Rings: 2Heavy Atoms: 11QED Weighted: 0.63Np Likeness Score: -1.37

References

1. Wang X, Choe Y, Craik CS, Ellman JA..  (2002)  Design and synthesis of novel inhibitors of gelatinase B.,  12  (16): [PMID:12127537] [10.1016/s0960-894x(02)00365-7]
2. Erlanson DA, McDowell RS, O'Brien T..  (2004)  Fragment-based drug discovery.,  47  (14): [PMID:15214773] [10.1021/jm040031v]
3. Murray M, Ryan AJ, Little PJ..  (1982)  Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.,  25  (8): [PMID:7120277] [10.1021/jm00350a002]
4. Giorgioni G, Accorroni B, Di Stefano A, Marucci G, Siniscalchi A, Claudi F.  (2005)  Benzimidazole, Benzoxazole and Benzothiazole Derivatives as 5HT2B Receptor Ligands. Synthesis and Preliminary Pharmacological Evaluation,  14  (2): [10.1007/s00044-005-0125-z]
5. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]
6.  (2018)  Lysyl oxidase-like 2 inhibitors and uses thereof, 
7. Park E, Song KH, Kim D, Lee M, Van Manh N, Kim H, Hong KB, Lee J, Song JY, Kang S..  (2022)  2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.,  13  (9.0): [PMID:36105338] [10.1021/acsmedchemlett.2c00256]